Late breaking abstracts – FLAURA study
The final analyses of two key trials – Checkmate 227, part 1 and FLAURA should help to position nivolumab + ipilimumab combination treatment and to reinforce osimertinib as… read more.
The final analyses of two key trials – Checkmate 227, part 1 and FLAURA should help to position nivolumab + ipilimumab combination treatment and to reinforce osimertinib as… read more.
For the second time this year, LungCancer.Med headed to Barcelona for the Annual European Society for Medical Oncology (ESMO) meeting. Written by Christine Clark
Developing CAR-T cells that are effective in solid tumours is challenging but experience in Hodgkin Lymphoma could pave the way for CAR-T cells in lung cancer. Bi-specific T-cell… read more.
Tumours use a variety of mechanisms to escape the host immune system and overcoming these to increase response rates and improve quality of life are key goals. Manipulation… read more.
Targeted treatments for mutation-driven non-small cell lung cancer have advanced considerably but many questions remain about how to use these drugs to the best advantage and how to… read more.
Immunotherapy has been hailed as a “game changer” in the treatment of lung cancer. As experience and understanding grows, optimal ways of delivering this type of treatment are… read more.
Immunotherapy now has an established place in treatment of non-small cell lung cancer but many questions remain such as the role of tumour mutational burden as a biomarker… read more.
“The genome can be thought of as the hardware driving a cell whereas the epigenome is more like the software – it is dynamic and erasable”, said Professor Ari… read more.
The first CAR T-cell treatment was administered in 2010 but the field has developed rapidly since then and in the first quarter of 2018 more than 100 trials… read more.
Checkmate 205, Cohort D. The results of the two-year, post-treatment follow-up of the Checkmate 205, Cohort D study group suggests that nivolumab followed by nivolumab + AVD could… read more.
Prof Peter Johnson (Southampton, UK) discusses where there is consensus and controversy in the management of HL in 2019, as well as talking about the key takeaways from his… read more.
Professor Andrew Davies (Southampton, UK) discussed his presentation on double hit lymphoma. Written by Christine Clark.